Lorillard downgraded to Underperform from Buy at CLSA CLSA downgraded Lorillard citing expectations for a more stringent FDA following the appointment of Mitch Zeller as the head of the FDA's Center for Tobacco Products. The analyst now sees the chance of a menthol ban at 10%-20% vs. 0% previously. Price target lowered to $42 from $49.
News For LO From The Last 14 Days
Check below for free stories on LO the last two weeks.
Subscribe for More Information
